Deucrava 6 mg of Introduction:

Each film coated tablet of Deucrava 6 mg contains Deucravacitinib INN 6 mg. Deucrava 6 mg is manufactured by Ziska Pharmaceuticals Ltd. and distributed globally by Orio Pharma. Deucravacitinib in used to treat moderate-to-severe plaque psoriasis in those who have not responded to systemic medications or phototherapy. Deucrava, where active substance is Deucravacitinib, is used to treat moderate to severe plaque psoriasis, a skin disease marked by persistent redness and white scales. 

Indication:

Deucrava is used to treat moderate-to-severe plaque psoriasis in individuals who do not respond to systemic medication or phototherapy. Limitation of use: Deucravacitinib should not be used with other powerful immunosuppressants. 

Therapeutic/Drug Class:

Topical Antifungal preparations, Tyrosine Kinase Inhibitor. 

Pharmacology:

Tyrosine kinase 2 (TYK2) is a protein in the human immune system that helps send signals throughout the body. This can induce irritation and buildup of skin cells, resulting in plaque formation. Deucrava  is an inhibitor of tyrosine kinase 2. Tyrosin Kinase 2 is part of the Janus kinase (JAK) family. Deucravacitinib binds to the regulatory domain of Tyrosine kinase 2, thereby stabilizing an inhibitory contact between the enzyme’s regulatory and catalytic domains. This leads in allosteric suppression of Tyrosine kinase 2 receptor-mediated activation and its downstream activation of signal transducers and activators of transcription (STATS), as demonstrated in cell-based studies. 

Dosage and Administration:

Recommended Evaluations and Immunizations Prior to treatment initiation: Before beginning Deucrava (Deucravacitinib)  medication, patients should be evaluated for active and latent tuberculosis (TB). If you test positive for tuberculosis, begin treatment before taking Deucrava.The suggested dosage for Deucravacitinib is 6 mg given orally once daily, with or without food. Avoid crushing, cutting, or chewing the tablets. Pediatric Use: The safety and efficacy in pediatric patients have yet to be proved. Geriatric Use: There were no significant variations in effectiveness between patients 65 years of age and older and younger adult patients. Deucravacitinib is not indicated for use in patients with severe hepatic impairment (Child-Pugh C). No dosage change is required for people with mild to moderate hepatic impairment.

Renal Impairment: Patients with mild, moderate, or severe renal impairment, as well as those on dialysis for end-stage renal disease (ESRD), should not be given any dose adjustments of Deucrava. 

Drug Interaction:

Clinical trials found no significant differences in the pharmacokinetics of Deucrava when administered with the following drugs: cyclosporine (dual Pgp/BCRP inhibitor), fluvoxamine (CYP1A2 inhibitor), ritonavir (CYP1A2 inducer), diflunisal (UGT1A9 inhibitor), pyrimethamine (OCT1 inhibitor), famotidine (H2 receptor antagonist), or rabeprazole (proton pump inhibitor). Rosuvastatin, methotrexate, mycophenolate mofetil (MMF), and oral contraceptives (norethindrone acetate and ethinyl estradiol) did not show any clinically relevant variations in pharmacokinetics when used in conjunction with Deucravacitinib. 

Contraindications: Deucrava is not recommended for patients who have a history of hypersensitivity responses to deucravacitinib or any of its excipients.

Side Effect: Upper respiratory infections, elevated blood creatine phosphokinase, herpes simplex, mouth ulcers, folliculitis, and acne are among the most prevalent side effects of Deucrava (Deucravacitinib).

Pregnancy & Lactation: There is no human data on Deucrava (Deucravacitinib)’s use in pregnant women.Based on its mechanism of action and observations in animals, it may cause embryofetal damage when taken to a pregnant woman. Females with reproductive potential should receive pregnancy testing before beginning. Advise females with reproductive potential to take effective contraception during therapy and for at least 30 days following the final dosage. Deucrava (Deucravacitinib) treatment may affect male fertility. Breastfeeding mothers should quit breastfeeding while taking Deucrava treatment and for at least one week after the final dosage due to unknown distribution of Deucrava 100 in human breast milk.

Overdose: There is no record of human overdosage with Deucrava (Deucravacitinib). Patients who overdose Deucrava (Deucravacitinib) should be closely watched and receive appropriate supportive treatment.  If any dose of Deucrava (Deucravacitinib) is missed, take the missed dose of Deucrava the same day you remember it. Take your next dose of Deucrava at the scheduled time and stick to your once-daily regimen. Do not take two doses at the same time.

Storage Conditions: Deucrava (Deucravacitinib) should be kept between 25°C and 30°C at room temperature. When a medication is no longer needed or has expired, dispose of it safely. Protect Deucrava (Deucravacitinib) from sunlight and humidity. Keep Deucrava (Deucravacitinib)  and all medicines out of the reach of children.

See more Oncology medicine visit our Shop